Success Metrics

Clinical Success Rate
69.2%

Based on 9 completed trials

Completion Rate
69%(9/13)
Active Trials
0(0%)
Results Posted
44%(4 trials)
Terminated
4(31%)

Phase Distribution

Ph phase_4
1
8%
Ph not_applicable
2
15%
Ph phase_1
2
15%
Ph phase_2
3
23%
Ph phase_3
3
23%

Phase Distribution

2

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
3(27.3%)
Phase 3Large-scale testing
3(27.3%)
Phase 4Post-market surveillance
1(9.1%)
N/ANon-phased studies
2(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

69.2%

9 of 13 finished

Non-Completion Rate

30.8%

4 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(9)
Terminated(4)

Detailed Status

Completed9
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
69.2%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 23 (27.3%)
Phase 33 (27.3%)
Phase 41 (9.1%)
N/A2 (18.2%)

Trials by Status

terminated431%
completed969%

Recent Activity

0 active trials
Showing 5 of 13
completed

Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

NCT00845273
completedphase_3

Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema

NCT01189461
completedphase_3

A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema

NCT01100307
completed

Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.

NCT00858208
completedphase_2

Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

NCT00239928
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT00845273

Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

Completed
NCT01189461Phase 3

Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema

Completed
NCT01100307Phase 3

A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema

Completed
NCT00858208

Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.

Completed
NCT00239928Phase 2

Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

Completed
NCT00346983Phase 1

Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics

Terminated
NCT00358423Phase 1

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

Terminated
NCT00150202Phase 3

Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)

Completed
NCT00088283Phase 2

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Completed
NCT00312351Phase 4

A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

Terminated
NCT00272766Not Applicable

Macugen for Histoplasmosis

Terminated
NCT00321997Phase 2

A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.

Completed
NCT00088192Not Applicable

Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13